1. Effects of dosing interval on the pharmacokinetic and pharmacodynamic interactions between the oral adsorbent AST-120 and triazolam in humans.
- Author
-
Kotegawa T, Tsutsumi K, Morita H, Imai H, Morita M, Yoshizato T, Ohyama T, Uchida S, Watanabe H, Namiki N, and Ohashi K
- Subjects
- Adsorption, Adult, Area Under Curve, Carbon pharmacokinetics, Cross-Over Studies, Drug Administration Schedule, Drug Interactions, Female, Humans, Hypnotics and Sedatives blood, Hypnotics and Sedatives pharmacokinetics, Male, Oxides pharmacokinetics, Triazolam blood, Triazolam pharmacokinetics, Young Adult, Carbon administration & dosage, Hypnotics and Sedatives administration & dosage, Oxides administration & dosage, Triazolam administration & dosage
- Abstract
Objective: The objective of this study was to evaluate the pharmacokinetic and pharmacodynamic interactions between the oral adsorbent AST-120 and triazolam., Methods: In this randomized, cross-over study, 12 healthy volunteers received a single oral dose of triazolam 0.25 mg alone or with AST-120 2 g given 0, 30 or 60 min before triazolam administration., Results: The area under the plasma triazolam concentration-time curve (AUC(0-∞)) significantly decreased with simultaneous AST-120 + triazolam (alone vs simultaneous: 10.9 ± 6.0 vs 6.4 ± 2.6 ng·h/mL, p = 0.003). Triazolam-induced impairment in psychomotor performance assessed by the digit symbol substitution test was significantly attenuated when AST-120 was administered simultaneously. No significant changes in pharmacokinetic and pharmacodynamic parameters were observed when AST-120 was given 30 or 60 min before triazolam administration., Conclusions: Administering AST-120 simultaneously with triazolam affects the pharmacokinetics and pharmacodynamics of triazolam. Dosing AST-120 at least 30 min before triazolam administration may avoid these interactions.
- Published
- 2012
- Full Text
- View/download PDF